SCHEMBL2978403

SCHEMBL2978403

CCOC(=O)N1CCC(O)C1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.51
THRB P10828 1/20 0.51
ATM Q13315 1/20 0.51
DPP4 P27487 2/20 0.49
NOS3 P29474 1/20 0.49
NOS2 P35228 1/20 0.49
ALDH1A1 P00352 3/20 0.49
CHRM1 P11229 1/20 0.47
TSHR P16473 1/20 0.47
TDP1 Q9NUW8 2/20 0.46
POLB P06746 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAPT P10636 3/20 0.45
PKM P14618 1/20 0.44
TP53 P04637 1/20 0.44
RECQL P46063 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL701943 1.00 GAA (0.56) GAAL3MBTL1THRBATMDPP4
Hydrochloric Acid SCHEMBL8307643 0.98 GAA (0.54) GAAL3MBTL1THRBATMDPP4
SCHEMBL13864821 0.89 ALDH1A1 (0.50) GAAL3MBTL1THRBATMNOS3
SCHEMBL8489223 0.89 ALDH1A1 (0.50) GAAL3MBTL1THRBATMNOS3
SCHEMBL1219954 0.88 GAA (0.65) GAAL3MBTL1THRBATMNOS3
SCHEMBL3652385 0.84 LMNA (0.54) GAAL3MBTL1THRBATMDPP4
SCHEMBL3652388 0.84 LMNA (0.54) GAAL3MBTL1THRBATMDPP4
SCHEMBL3708900 0.84 LMNA (0.54) GAAL3MBTL1THRBATMDPP4
SCHEMBL28220372 0.84 DPP4 (0.42) GAAL3MBTL1THRBATMDPP4
SCHEMBL6509490 0.84 GAA (0.48) GAAL3MBTL1THRBATMNOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022056449-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION (US) 2022-03-17 WO disclosed
EP-1950198-B1 PROCESS FOR PRODUCTION OF BENZYLOXYPYRROLIDINE DERIVATIVE, AND PROCESS FOR PRODUCTION OF HYDROCHLORIDE SALT POWDER OF OPTICALLY ACTIVE BENZYLOXYPYRROLIDINE DERIVATIVE TORAY FINECHEMICALS CO LTD (JP) 2014-08-06 EP disclosed
CN-101300228-B Process for production of benzyloxypyrrolidine derivative, and process for production of hydrochloride salt powder of optically active benzyloxypyrrolidine derivative TORAY FINECHEMICALS CO LTD 2013-05-08 CN disclosed
US-7772406-B2 Process for production of benzyloxypyrrolidine derivative, and process for production of hydrochloride salt powder of optically active benzyloxypyrrolidine derivative TORAY FINE CHEMICALS CO., LTD. (JP) 2010-08-10 US disclosed
US-20090093643-A1 Process for Production of Benzyloxypyrrolidine Derivative, and Process for Production of Hydrochloride Salt Powder of Optically Active Benzyloxypyrrolidine Derivative TORAY FINE CHEMICALS CO., LTD. (JP) 2009-04-09 US disclosed
CN-101300228-A Process for production of benzyloxypyrrolidine derivative, and process for production of hydrochloride salt powder of optically active benzyloxypyrrolidine derivative TORAY FINECHEMICALS CO LTD (JP) 2008-11-05 CN disclosed
EP-1950198-A1 PROCESS FOR PRODUCTION OF BENZYLOXYPYRROLIDINE DERIVATIVE, AND PROCESS FOR PRODUCTION OF HYDROCHLORIDE SALT POWDER OF OPTICALLY ACTIVE BENZYLOXYPYRROLIDINE DERIVATIVE Toray Fine Chemicals Co., Ltd. (JP) 2008-07-30 EP disclosed
EP-0974602-B1 Catalyst and process for hydrogenating olefinically unsaturated compound JSR CORP (JP) 2004-01-02 EP disclosed
US-6291596-B1 CONTACTING OLEFINICALLY UNSATURATED COMPOUND WITH HYDROGEN IN THE PRESENCE OF A HYDROGENATION CATALYST COMPRISING TITANIUM OR ZIRCONIUM OR HAFNIUM COMPOUND IN AN INERT, ORGANIC SOLVENT JSR CORPORATION (JP) 2001-09-18 US disclosed
EP-0974602-A1 Catalyst and process for hydrogenating olefinically unsaturated compound JSR Corporation (JP) 2000-01-26 EP disclosed
US-5883102-A Pharmaceutically active compounds ASTRA PHARMACEUTICALS LIMITED (GB) 1999-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093643-A1 Process for Production of Benzyloxypyrrolidine Derivative, and Process for Production of Hydrochloride Salt Powder of Optically Active Benzyloxypyrrolidine Derivative HPD, PAH, DHPS GAA 1235/4885L3MBTL1 3977/4885THRB 3615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.